Skip to main content

Table 1 Efficacy inputs with medication discontinuation at 8.6 months [Source: elaborated from Samuelson et al 2019 [16]]

From: Cost-utility analysis of trabecular micro-bypass stents (TBS) in patients with mild-to-moderate open-angle Glaucoma in Italy

Time (years)

iStent + Cataract surgery

Cataract surgery

IOP (mmHg)

IOP reduction (mmHg)a

IOP (mmHg)

IOP reduction (mmHg)a

0

24.8b

–

24.5**

–

1

17.7

7.1b

19.0

5.5b

2

18.3

6.6b

20.1

4.4b

3

19.1

5.7

20.9

3.6

4

19.4

5.4

21.2

3.3

5

19.7

5.1

21.3

3.2

6

20.0

4.8

21.5

3.0

7

20.3

4.5

21.7

2.8

8

20.5

4.3

21.8

2.7

9

20.8

4.0

22.0

2.5

10

21.0

3.8

22.1

2.4

10+

21.2

3.6

22.2

2.3

  1. IOP intraocular pressur
  2. Values after 2 years are based on expert opinions
  3. aIntraocular pressure reduction vs. baseline
  4. bIOP and IOP reduction data, at one and two years, were obtained from the randomized clinical trial (RCT) conducted by Samuelson et al 2019 [16] and adjusted for the time-to-discontinuation. Baseline IOP: 24.8 ± 3.3 mmHg vs. 24.5 ± 3.1 mmHg in the iStent + Cataract surgery vs. Cataract surgery groups, respectively (P = 0.33)
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us